BI-D1870, a specific inhibitor of RSK2 N-terminal kinase domain (NTKD), induced growth inhibition and apoptosis in MCL lines, suggesting RSK2 NTKD as a potential therapeutic target in MCL [190]. Here, RPS6KA3 is linked to mantle cell lymphoma.